Find and Pitch Jounalists, Get Your Story Covered

Tags: risk insurance allianz gmd geomagnetic disturbance

	Profile	Recent Articles on Subject
1	Kristen Monaco MedPage Today	Psilocybin Paper Corrected; Fewer Psychiatrists Billing Medicare; Cannabis and Death - 21 days ago FDA Rejects MDMA-Assisted Therapy for PTSD - 7 months ago Psychedelics for Psych Conditions Made Their Mark in 2023 - about 1 year ago Another Mid-Stage Psychedelic Win; Gun Suicides Reach High; Magnetic Seizure Therapy - about 1 year ago
2	Meagan Parrish Pharma Voice Senior editor @industrydive. Pharma world follower. Wisconsin, USA pharmaceuticalsjournalismparenting	Psychedelics haven’t fulfilled clinical expectations, but new trial strategies could turn the tide - 3 months ago Despite adcomm rejection, Lykos CEO sees future for MDMA drug - 9 months ago
3	Marissa Plescia MedCity News Reporter at MedCity News. reportingjournalism	4 Things Employers Should Know About Psychedelic Medicines - 4 months ago What’s Next for Psychedelic Medicines? - 4 months ago
4	Meghana Keshavan STAT News Biotech nerd and writer @statnews. biotechwriting	STAT+: Rick Doblin, ‘unleashed,’ blasts FDA over Lykos drug rejection and turns to global push for MDMA therapy - 7 months ago STAT+: Lykos Therapeutics cuts 75% of staff after FDA rejects MDMA-assisted therapy - 7 months ago A tough week for MDMA-assisted psychotherapy - 7 months ago STAT+: Three MDMA therapy papers retracted over data integrity concerns - 7 months ago FDA rejects MDMA as a psychedelic treatment for PTSD - 7 months ago Psychedelic investment continues to ramp up - about 1 year ago
5	Emily Mullin Wired Staff writer at WIRED. Covers biotechnology. Fall 2021 fellow. Pittsburgh, Pennsylvania biotechnology	The Uncertain Path Forward for Psychedelic Medicine - 7 months ago The FDA Just Rejected a Bid for MDMA to Treat PTSD - 7 months ago
6	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	Listen: Drug pricing drops & psychedelics under fire - 7 months ago
7	Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. biopharmastartupsventure capital	Listen: Drug pricing drops & psychedelics under fire - 7 months ago
8	Elaine Chen STAT News Reporter at STATnews. Formerly at Business Insider. Chicago, Illinois journalism	Listen: Drug pricing drops & psychedelics under fire - 7 months ago
9	Oshan Jarow Vox Focus on consciousness, economics. Co-founder LE Possibility. Brooklyn, New York consciousnesseconomicspodcasting	MDMA therapy didn’t get FDA approval. Now what? - 7 months ago How should we sell psychedelics? - 8 months ago Psychedelics are about to become a casualty of Oregon’s opioid crisis - 12 months ago Robin Carhart-Harris studies psychedelics to understand the mind - over 1 year ago Psychedelics can have enormous benefits, but the risks shouldn’t be ignored - over 1 year ago
10	N. Adam Brown MD MedPage Today Healthcare Strategist/Communicator. Washington, D.C. Healthcarestrategycommunication	The Promise of 'Magic Mushrooms' for Mental Health Is Real - 7 months ago

Journalists covering Psychedelic Pharmacists Association